The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta‐analysis

Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis

(2018) Daniel Kantor et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Multiple Sclerosis

(2018) Daniel S. Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives

(2018) Andrea Huwiler et al.   PHARMACOLOGY & THERAPEUTICS

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies

(2018) Gwendoline Montes Diaz et al.   AUTOIMMUNITY REVIEWS

Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System

(2018) Kristin M. Galetta et al.   MEDICAL CLINICS OF NORTH AMERICA

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

(2017) Giancarlo Comi et al.   JOURNAL OF NEUROLOGY

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy

(2016) Alice Laroni et al.   NEUROLOGICAL SCIENCES

Immunological treatment of multiple sclerosis

(2016) Martin Diebold et al.   SEMINARS IN HEMATOLOGY

Disease modifying therapies for relapsing multiple sclerosis

(2016) Dean M Wingerchuk et al.   BMJ-British Medical Journal

Disease modifying therapies for relapsing multiple sclerosis

(2016) Dean M Wingerchuk et al.   BMJ-British Medical Journal

Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations

(2014) Mark S. Freedman et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Magnetic resonance outcome measures in multiple sclerosis trials

(2014) Massimo Filippi et al.   CURRENT OPINION IN NEUROLOGY

Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort

(2014) R. A. Alroughani et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

(2014) Edward Fox et al.   Multiple Sclerosis and Related Disorders

Long-term safety of fingolimod: Interim evaluation of data from the longterms trial

(2014) P.V. Rosenstiel et al.   Multiple Sclerosis and Related Disorders

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

(2013) Stefan Braune et al.   JOURNAL OF NEUROLOGY

Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod

(2012) N.S. Roskell et al.   CURRENT MEDICAL RESEARCH AND OPINION

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

(2012) T Saida et al.   Multiple Sclerosis Journal

Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis

(2011) Fabiola Del Santo et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Risk of Arterial Cardiovascular Diseases in Patients with Multiple Sclerosis: A Population-Based Cohort Study

(2010) Christian Fynbo Christiansen et al.   NEUROEPIDEMIOLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

(2009) Volker Brinkmann   BRITISH JOURNAL OF PHARMACOLOGY

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

(2009) G. Comi et al.   Multiple Sclerosis Journal